Bryan Roberts, Ph.D.

Bryan Roberts, Ph.D.

Partner, Venrock Associates

Bryan Roberts, Ph.D. joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock's Palo Alto office and focuses on a broad range of healthcare investments. Bryan currently serves on the Board of Directors of Ironwood Pharmaceuticals (NASDAQ: IRWD) as well as a number of private companies including Achaogen, Castlight Health, Ikaria, Satiety, Vitae Pharmaceuticals and Zeltiq. Past investments include athenahealth (NASDAQ: ATHN), Illumina (NASDAQ: ILMN), Sirna Therapeutics (acquired by Merck) and Xenoport (NASDAQ: XNPT). Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College. Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006, to healthspottr’s 2009 Future Health 100 list and was the highest-ranking healthcare investor on Forbes’ Midas List in 2008 and 2009.